Literature DB >> 11488722

Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery?

A Minervini1, L Lilas, G Morelli, C Traversi, S Battaglia, R Cristofani, R Minervini.   

Abstract

OBJECTIVES: To evaluate the role of regional lymph node dissection (LND) in a series of patients with renal cell carcinoma (RCC) with no suspicion of nodal metastases before or during surgery. PATIENTS AND METHODS: A series of 167 patients with RCC, free from distant metastases at diagnosis, and who underwent radical nephrectomy at our hospital between January 1990 and October 1997, was reviewed. The mean (median, range) follow-up was 51 (45, 19-112) months. Of the 167 patients, 108 underwent radical nephrectomy alone and 59 had radical nephrectomy with regional LND limited to the anterior, posterior and lateral sides of the ipsilateral great vessel, from the level of the renal pedicle to the inferior mesenteric artery. Of these 59 patients, 49 had no evidence of nodal metastases before or during surgery. The probability of survival was estimated by the Kaplan-Meier method, using the log-rank test to estimate differences among levels of the analysed variables.
RESULTS: The overall 5-year survival was 79%; the 5-year survival rate for the 108 patients who underwent radical nephrectomy alone was 79% and for the 49 who underwent LND was 78%. Of the 49 patients with no suspicion of lymph node metastases, one (2%) was found to have histologically confirmed positive nodes.
CONCLUSION: These results suggest that there is no clinical benefit in terms of overall outcome in undertaking regional LND in the absence of enlarged nodes detected before or during surgery.

Entities:  

Mesh:

Year:  2001        PMID: 11488722     DOI: 10.1046/j.1464-410x.2001.02315.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  14 in total

Review 1.  [Lymph node dissection in patients with renal cell carcinoma].

Authors:  T Ebert; D Schnell; L Weissbach
Journal:  Urologe A       Date:  2005-06       Impact factor: 0.639

2.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

Review 3.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

4.  Role of lymphadenectomy for patients undergoing radical nephrectomy for renal cell carcinoma.

Authors:  Stephen J Freedland; Jean B Dekernion
Journal:  Rev Urol       Date:  2003

5.  Lymph node dissection in patients with kidney cancer: when is it indicated?

Authors:  Ganesh S Palapattu; Hyung L Kim; Arie S Belldegrun
Journal:  Rev Urol       Date:  2003

6.  Concurrent RCC with tuberculous para-aortic lymphadenopathy: A pleasant surprise.

Authors:  Praveen Pushkar; Anshuman Agarwal; Ashok Sarin; Vikas Kashyap
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 7.  Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies.

Authors:  Christopher Montemagno; Frédéric Luciano; Gilles Pagès
Journal:  Methods Mol Biol       Date:  2022

Review 8.  The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis.

Authors:  Xu Shi; Dechao Feng; Dengxiong Li; Facai Zhang; Wuran Wei
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

Review 9.  Long-term outcomes of the surgical management of renal cell carcinoma.

Authors:  John S Lam; Arie S Belldegrun; Allan J Pantuck
Journal:  World J Urol       Date:  2006-02-15       Impact factor: 4.226

Review 10.  [Value of lymph node dissection for renal cell carcinoma].

Authors:  I Matuschek; A S Merseburger; M A Kuczyk
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.